



3RD INTERNATIONAL SYMPOSIUM ON:

Palazzo Ximènes Panciatichi Florence (Italy)

May 11th -13th 2017

THE CALCIUM SENSING RECEPTOR (CASR)



ORGANIZED BY:

UNIVERSITY OF FLORENCE

Florence, Italy

MEDICAL UNIVERSITY OF VIENNA Vienna, Austria UNIVERSITY OF OXFORD Oxford, UK UNIVERSITY OF CALIFORNIA San Francisco CA, USA The symposium will bring together basic, translational and clinical scientists from different disciplines who study the molecular biology, physiology and pathophysiology of the CaSR and clinical disorders of CaSR function.

The program will feature recent research on the role of the CaSR in e.g. skeletal physiology, vascular calcification, pulmonary function, neuronal injury, parathyroid physiology, mineral metabolism, exocrine and transport functions in the gut and kidney, skin biology and cancer cell signalling. Clinical uses of CaSR modulators to treat human disorders, structural and signaling aspects of the CaSR and interactions between the CaSR and other GPCRs will be highlights.

The program will include lectures from keynote speakers, oral presentations, poster discussion sessions and forums for young investigators to meet senior experts.

Maria Luisa Brandi, Enikö Kállay, Rajesh V. Thakker and Wenhan Chang Co-Presidents of the Symposium

WITH THE ENDORSEMENT OF



Ministero della Salute









PRESIDENTS OF THE MEETING

Maria Luisa BRANDI

University of Florence

Unity of Bone and Mineral Metabolism Diseases *Florence (Italy)*

Enikö KÁLLAY

Medical University of Vienna

Department of Pathophysiology and Allergy Research Vienna (Austria)

Wenhan CHANG

University of California

UCSF Endocrinology & Metabolism Department of Medicine San Francisco CA (USA)

Rajesh V. THAKKER

University of Oxford

Nuffield Department of Medicine Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) Churchill Hospital Headington Oxford (UK)

INTERNATIONAL SCIENTIFIC COMMITTEE

- · Hans Bräuner-Osborne
- · Michael T. Collins
- · Arthur Conigrave
- · Rachel I. Gafni
- · Edward F. Nemeth
- · Dolores Shoback
- · John J. Wysolmerski

PROMOTED BY

Fondazione Internazionale Menarini

Centro Direzionale Milanofiori Edificio L – Strada 6 20089 Rozzano (Milan, Italy) Phone: +39 02 55308110

Phone: +39 02 55308110 Fax: +39 02 55305739

E-mail: milan@fondazione-menarini.it

ORGANIZING SECRETARIAT

I&C s.r.l.

Via Andrea Costa, 202/6 - 40134 Bologna (Italy) Phone: +39 051 6144004 Fax: +39 051 6142772

E-mail: stefania.parolari@iec-srl.it; giulia.delia@iec-srl.it

www.iec-srl.it

PROGRAMME

THURSDAY, MAY 11[™] - AFTERNOON

OPENING CEREMONY

01.30 p.m.

Welcome addresses and Presentation of the 4th Parathyroid Medal of FIRMO Foundation Maria Luisa Brandi (Florence, I)
Wenhan Chang (San Francisco CA, USA)
Enikö Kállay (Vienna, A)
Rajesh V. Thakker (Oxford, UK)

SESSION I - CALCIUM CASR SIGNALLING

Chairpersons:	Frank Bruggeman (Amsterdam, NL) Ernesto Carafoli (Padua, I)
02.00 p.m.	Dolores Shoback (San Francisco CA, USA) The CaSR discovery opens way to the future
02.30 p.m.	Arthur Conigrave (Sydney, AUS) Biased signalling from CaSR
03.00 p.m.	Hans Bräuner-Osborne (Copenhagen, DK) Trans-activation and allosteric modulation of the calcium-sensing receptor
03.30 p.m.	Donald Ward (Manchester, UK) Cell-specific CaSR signalling: effector feedback modulation of receptor responsiveness
04.00 p.m.	Leonidas Tsiokas (Edmond OK, USA) Regulation of CaSR by TRPC1 channels
04.30 p.m.	Coffee Break

SESSION II – PHARMACOLOGY OF THE CASR

Chairpersons:	Maria Luisa Brandi (Florence, I) Sandra Petraglia (Roma, I)
05.00 p.m.	Gerda E. Breitwieser (Danville PA, USA) Pharmacoferones
05.30 p.m.	Edward F. Nemeth (Toronto, CDN) Calcimimetic and Calcilytic Drugs
06.00 p.m.	Letizia Vannucci (Florence, I) Parathyroid cell lines: a model for in vitro drug testing
06.30 p.m.	PLENARY LECTURE Rajesh V. Thakker (Oxford, UK) introduces: Allen M. Spiegel (New York NY, USA) Calcium actions and its regulators: from basic research to clinical applications
07.15 p.m.	Welcome cocktail

FRIDAY, MAY 12TH - MORNING

SESSION III – THE ROLE OF CASR IN THE PATHOGENESIS OF CALCITROPIC DISORDERS

Chairpersons:	Laura Masi (Florence, I) Dolores Shoback (San Francisco CA, USA)
08.30 a.m.	Rajesh V. Thakker (Oxford, UK) CaSR signalling pathways and hypercalcemia in humans
09.00 a.m.	Michael Mannstadt (Boston MA, USA) CaSR and Gα11 in hypoparathyroidism in humans
09.30 a.m.	Giuseppe Vezzoli (Milan, I) Kidney disorders
10.00 a.m.	David Goltzman (Montreal, CDN) Bone diseases
10.30 a.m.	Coffee break

SESSION IV - ORAL COMMUNICATIONS AND HOT TOPICS

Chairpersons:	Luisella Cianferotti (Florence, I) Geoffrey N. Hendy (Montreal, CDN)
11.00 a.m.	Caroline M. Gorvin (Oxford, UK) Studies of an autosomal dominant hypocalcemia Type-1 (Adh1) associated Calcium-sensing Receptor (CaSR) mutation, ARG680GLY, provides insights into biased signalling
11.15 a.m.	Martin Schepelmann (Cardiff, UK) Altered mineral ion metabolism in a mouse model of targeted CaSR deletion from vascular smooth muscle cells
11.30 a.m.	Sarah Howles (Oxford, UK) Mice with an inactivating ASP195GLY mutation in G-protein Subunit Alpha-11 (Gα11) are a model for familial hypocalciuric hypercalcaemia type 2 (FHH2)
11.45 a.m.	Polina Yarova (Cardiff, UK) Towards the repurposing existing clinical-grade calcilytics for allergic asthma
12.00 p.m.	Nariman Balenga (Baltimore MD, USA) Orphan adhesion GPCR GPR64 regulates CaSR function in parathyroid
12.15 p.m.	Marianna Ranieri (Bari, Italy) A Novel CaSR- dependent microRNA pathway is involved in the downregulation of AQP2 expression contributing to volume depletion in Pendrin/Na-Cl cotransporter dKO mice
12.30 p.m.	Lunch and poster discussion

FRIDAY, MAY 12TH – AFTERNOON

SESSION V - PRECLINICAL MODELS

Chairpersons:	Arthur Conigrave (Sydney, AUS) Donald Ward (Manchester, UK)
02.00 p.m.	Qing R. Fan (New York NY, USA) Crystal structure of CaSR
02.30 p.m.	Wenhan Chang (San Francisco CA, USA) CaSR/GABAbR1 heteromers mediate PTH hypersecretion in hyperparathyroidism
03.00 p.m.	Fadil M. Hannan (Liverpool, UK) Mouse models for ADH1 and ADH2
03.30 p.m.	Caroline Gorvin (Oxford, UK) Stable cell lines expressing adaptor protein 2 mutations to investigate signalling pathways
04.00 p.m.	Coffee break

SESSION VI - CALCITROPIC DISORDERS: NEWS IN MEDICAL TREATMENT

Chairpersons:	Rachel I. Gafni (Bethesda MD, USA) Andrea Lenzi (Rome, I)
04.30 p.m.	John P. Bilezikian (New York NY, USA) Primary hyperparathyroidism
05.00 p.m.	Masafumi Fukagawa (Isehara, J) Secondary hyperparathyroidism
05.30 p.m.	Maria Luisa Brandi (Florence, I) Hypoparathyrodism
06.00 p.m.	Michael T. Collins (Bethesda MD, USA) Treatment for ADH1 in humans

SESSION VII – NON CALCITROPIC DISORDERS: DIGESTIVE AND SKIN FUNCTION

Chairpersons:	Enikö Kállay (Vienna, A) Francesco Tonelli (Florence, I)
06.30 p.m.	Chia-Ling Tu (San Francisco CA, USA) Role of CaSR in skin wound healing
07.00 p.m.	James J. Pestka (East Lansing MI, USA) Control of gastroenteric hormones by CaSR
07.30 p.m.	Sam Cheng (Gainesville FL, USA) The role of the CaSR in gastrointestinal inflammation

SATURDAY MAY 13TH - MORNING

SESSION VIII - NON CALCITROPIC DISORDERS: BLOOD VESSELS AND LUNG


Chairpersons:	Dolores Shoback (San Francisco CA, USA) Elisabetta Cerbai (Florence, I)
08.00 a.m.	Harry Z.E. Greenberg (London, UK) Nitric oxide signalling mediates CaSR-induced vasodilatations
08.30 a.m.	Y.S. Prakash (Rochester MN, USA) Calcium sensing receptor in perinatal airway disease

SESSION IX - NON CALCITROPIC DISORDERS: CANCER

Chairpersons:	Wenhan Chang (San Francisco CA, USA) Romuald Mentaverri (Amiens, F)
09.00 a.m.	John J. Wysolmerski (New Haven CT, USA) CaSR actions on PTHrP in breast cancer
09.30 a.m.	Enikö Kállay (Vienna, A) The role of the CaSR in colon cancer
10.00 a.m.	Carmen de Torres (Barcelona, E) The role of the CaSR in neuroblastoma
10.30 a.m.	Coffee break

SESSION X – FUTURE DEVELOPMENTS FOR CASR TARGETED THERAPIES

Chairpersons:	Hans Bräuner-Osborne (Copenhagen, DK) Fadil M. Hannan (Liverpool, UK)
11.00 a.m.	Daniela Riccardi (Cardiff, UK) Asthma
11.30 p.m.	Seiji Fukumoto (Tokushima, J) Glucose metabolism
12.00 p.m.	Katie Leach (Melbourne, AUS) Rational design of CaSR therapeutics for diverse disorders
12.30 p.m.	Lunch and poster discussion
03.00 p.m.	CONCLUDING REMARKS Maria Luisa Brandi (Florence, I) Wenhan Chang (San Francisco CA, USA) Enikö Kállay (Vienna, A) Rajesh V. Thakker (Oxford, UK)



ASBMR YOUNG INVESTIGATOR AWARD WINNERS

Halah Albar
Signal crosstalk between CaSR and gs-coupled receptors

Sarah Brennan

Molecular requirements for temperature dependent changes in CaSRinduced Ca2+i oscillations

Annarita Di Mise

CaSR is functionally expressed in conditionally immortalized proximal tubular epithelial cells (ciPTEC) deficient for polycystin 1 or derived from ADPKD1 patients, representing a possible therapeutic target

Anna Gluck
Systematic in silico evaluation of rare genetic variants in G-Protein alpha 11

Caroline M. Gorvin ASBMR Young investigator top scoring abstract

Studies of an autosomal dominant hypocalcemia type-1 (adh1) associated calcium-sensing receptor (CaSR) mutation, ARG680GLY, provides insights into biased signalling

Sarah Howles

Mice with an inactivating ASP195GLY mutation in G-Protein subunit alpha-11
(Gα11) are a model for familial hypocalciuric hypercalcaemia type 2 (fhh2)

Mie Kronborg Olesen

Extracellular domain calcium-sensing receptor (CaSR) mutations leading to hypercalcemic and hypocalcemic disorders cluster at the homodimeric interface

Preeti Sharma

CaSR protein expression analysis in stem cells derived from human skeletal muscle and human adipose tissue

Martin Schepelmann

Altered mineral ion metabolism in a mouse model of targeted CaSR deletion from vascular smooth muscle cells

GENERAL INFORMATION

Meeting venue

The venue for the Meeting will be Palazzo Ximènes Panciatichi, Via Borgo Pinti, 68 - 50121 Florence (Italy)

Accommodation

It is possible to book a room at a special rate using the Florence Convention Bureau website (http://www.florencecongressbooking.com/index/en.shtml) indicating the code CASR2017.

Secretariat during the Meeting

The Secretariat will be open at the following times: Thursday, May 11^{TH} , from 10.30 a.m. to 07.45 p.m. Friday, May 12^{TH} , from 08.00 a.m. to 08.00 p.m. Saturday, May 13^{TH} , from 08.00 a.m. to 01.30 p.m.

Official language

The official language of the Meeting will be English.

Registration

The Meeting is free to attend.

Technical facilities speakers

Facilities will be available for computer presentations and overhead projections. A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentations to the business center at least one hour before the session starts.

The slide center will be open at the following times:

Thursday, May 11^{TH} , from 10.30 a.m. to 07.45 p.m. Friday, May 12^{TH} , from 08.00 a.m. to 08.00 p.m. Saturday, May 13^{TH} , from 08.00 a.m. to 01.30 p.m.

Lunches and coffee breaks

Lunches and coffee breaks will be served in the Meeting area.

Abstracts book

Participants will receive the Abstract book at the Meeting.

European CME Credits

EACCME credits have been requested for May 11TH-12TH-13TH for the following disciplines: Internal Medicine, Metabolic and Diabetes Diseases, Rheumatology, Clinical Biochemistry, Endocrinology, Andrology and Reproduction Medicine.

EACCME credits



The '3rd International Symposium on: The Calcium-Sensing Receptor (CaSR)' was granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Event code: 15527

The '3rd International Symposium on: The Calcium-Sensing Receptor (CaSR) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The '3rd International Symposium on: The Calcium-Sensing Receptor (CaSR)' is designated for a maximum of 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

FACCMF credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

LIST OF CHAIRPERSONS, SPEAKERS, CO-PRESIDENTS OF THE SYMPOSIUM

John P. BILEZIKIAN

Columbia University College of Physicians & Surgeons Department of Medicine Division of Endocrinology Metabolic Bone Diseases Unit New York Presbyterian Hospital New York NY (USA)

Maria Luisa BRANDI

University of Florence Unity of Bone and Mineral Metabolism Diseases Florence (Italy)

Hans BRÄUNER-OSBORNE

University of Copenhagen
Department of Drug Design and
Pharmacology
Faculty of Health and Medical Sciences
Copenhagen (Denmark)

Gerda E. BREITWIESER

Weis Center for Research/Geisinger Clinic/Molecular and Functional Genomics Danville PA (USA)

Frank BRUGGEMAN

University of Amsterdam Amsterdam (The Netherlands)

Ernesto CARAFOLI

University of Padua Venetian Institute of Molecular Medicine Padua (Italy)

Elisabetta CERBAI

University of Florence Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA) Florence (Italy)

Wenhan CHANG

University of California UCSF Endocrinology & Metabolism Department of Medicine San Francisco CA (USA)

Sam CHENG

University of Florida Department of Pediatrics Gainesville FL (USA)

Luisella CIANFEROTTI

University of Florence Department of Surgery and Translational Medicine Unit of Bone and Mineral Diseases Florence (Italy)

Michael T. COLLINS

National Institutes of Health Section on Skeletal Disorders and Mineral Homeostasis National Institute of Dental and Craniofacial Research Bethesda MD (USA)

Arthur CONIGRAVE

University of Sydney Faculty of Medicine Sydney (Australia)

Carmen DE TORRES

Hospital Sant Joan de Déu Department of Oncology Barcelona (Spain)

Qing Rong FAN

Columbia University
Department of Pharmacology
New York NY (USA)

Masafumi FUKAGAWA

Tokai University School of Medicine Isehara (Japan)

Seiji FUKUMOTO

Tokushima University Fujii Memorial Institute of Medical Sciences Tokushima (Japan)

Rachel I. GAFNI

National Institutes of Health Section on Skeletal Disorders and Mineral Homeostasis National Institute of Dental and Craniofacial Research Bethesda MD (USA)

David GOLTZMAN

McGill University
McGill University Health Centre
Calcium Research Lab
Montreal (Canada)

Caroline GORVIN

University of Oxford Academic Endocrine Unit Oxford (United Kingdom)

Harry Z.E. GREENBERG

St George's University of London London (United Kingdom)

Fadil M. HANNAN

University of Liverpool Institute of Ageing and Chronic Disease Liverpool (United Kingdom)

Geoffrey N. HENDY

McGill University
Department of Physiology and
Human Genetics
Montreal, Canada

Enikö KÁLLAY

Medical University of Vienna Department of Pathophysiology and Allergy Research Vienna (Austria)

Katie LEACH

Monash University Monash Institute of Pharmaceutical Sciences Melbourne (Australia)

Andrea LENZI

Department of Experimental Medicine Sapienza University of Rome Policlinico Umberto I Rome (Italy)

Michael MANNSTADT

Endocrine Unit Harvard Medical School Massachusetts General Hospital Boston MA (USA)

Laura MASI

University Hospital AOU-Careggi Metabolic Bone Diseases Unit Florence (Italy)

Romuald MENTAVERRI

Universitary research Center in Health (CURS)
CHU Amiens
Amiens (France)

Edward F. NEMETH

Independent Consultant *Toronto (Canada)*

James J. PESTKA

Michigan State University Department of Food Science and Human Nutrition East Lansing MI (USA)

Sandra PETRAGLIA

Director Bureau Indipendent Research AIFA

Yedatore S. PRAKASH

Mayo Clinic Physiology and Biomedical Engineering Rochester MN (USA)

Daniela RICCARDI

Cardiff University
School of Biosciences
Cardiff (United Kingdom)

Dolores SHOBACK

Division of Endocrinology University of California San Francisco CA (USA)

Allen M. SPIEGEL

Albert Einstein College of Medicine Montefiore Medicine New York NY (USA)

Rajesh V. THAKKER

University of Oxford Nuffield Department of Clinical Medicine, OCDEM Churchill Hospital Headington, Oxford (UK)

Francesco TONELLI

General Surgery University of Florence Florence (Italy)

Leonidas TSIOKAS

Department of Cell Biology Regulation of CaSR function by the TRPC1 channel University of Oklahoma Health Sciences Center Oklahoma City, OK (USA)

Chia-ling TU

Department of Medicine University of California Endocrine Research Unit San Francisco VA Medical Center San Francisco CA (USA)

Letizia VANNUCCI

University of Florence Unity of Bone and Mineral Metabolism Diseases Florence (Italy)

Giuseppe VEZZOLI

San Raffaele Scientific Institute Nephrology and Dialysis Unit *Milan (Italy)*

Donald WARD

University of Manchester Faculty of Biology, Medicine and Health Manchester (United Kingdom)

John J. WYSOLMERSKI

Section of Endocrinology and Metabolism Department of Internal Medicine Yale School of Medicine New Haven CT (USA)

